Clinical, radiological and pathological evaluation of residual disease in women receiving neoadjuvant chemotherapy for locally advance carcinoma breast

Mayank Mishra; Puspendra Singh; Alok Tripathi

doi:10.18203/2349-2902.isj20180346

Authors

Mayank Mishra Department of Surgery, Heritage Institute of Medical Sciences Varanasi, Utter Pradesh, India
Puspendra Singh Department of Surgery, Heritage Institute of Medical Sciences Varanasi, Utter Pradesh, India
Alok Tripathi Department of Surgery, Heritage Institute of Medical Sciences Varanasi, Utter Pradesh, India

DOI:

https://doi.org/10.18203/2349-2902.isj20180346

Keywords:

LABC, Chemotherapy, Clinical, Evaluation, Pathological, Radiological

Abstract

Background: Egyptians were first to note this disease, 3,500 years ago and described fairly accurately in George Ebers papyri. This disease occurs almost entirely in women, but men can get it, too. Breast cancer is most common among women worldwide. In India, its second after cancer cervix. Its incidence outranks all other cancers in women >35 years of age. Age adjusted incidence rates vary from 9.7- 28.2/100,000. The treatment of locally advanced breast cancer has considerably changed and now includes a multidisciplinary approach, which is directed both to locoregional control and destruction of distant micro-metastasis. Neoadjuvant therapy causes a reduction in size of primary tumor allowing more conservative surgical approach without any increase in locoregional recurrence rate. Limitations of clinical methods for assessment of response to neoadjuvant chemotherapy have now incorporated by imaging and pathological method.

Methods: In present study author assess LABC clinically, radiologically and pathologically by mammography USG, FNAC and histopathologic examination, pre- and post-neoadjuvant chemotherapy and evaluate response to chemotherapy, reduction of tumor volume and prior assessment of the patient’s prognosis.

Results: Present study shown USG is more accurate in assessing residual disease in post neoadjuvant chemotherapy in defining the real extent of residual disease and also superior in term of detecting complete pathological response.

Conclusions: A multimodal assessment of response of neoadjuvant chemotherapy is needed to direct optimal surgical treatment with acceptable cosmesis.

Metrics

Metrics Loading ...

References

Vinicombe SJ, Mac Vikar AD, Guy RL. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathological correlation. Radiol. 1996;198:333-40.

Brito RA, Valero V, Budzar AU. Long term results of combined modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases; the University of Texas M.D. Anderson Cancer Center experience. J Clinc. Oncol. 2001;19:628-33.

Singlerity SE, Allred C, Ashley P. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clinc Oncol. 2002;20:3628-36.

Shannon M, McDonald MD. American College of Radiology; ACR Appropriateness Crireria. 2011.

Katia HH, Sonia MM. Monitoring the response to neoadjuvant chemotherapy. 2013.

Haagensen C, Stout A. Carcinoma of Breast II. Criteria of operability. Ann Surg.1943;118:859-61.

McCready DR, Hortobagyi GN, Kau SW. The prognostic significance of lymphnode metastases after preoperative chemotherapy for locally breast cancer. Arch Surg.1989;124:21-5.

Cristofanilli M, Gonzalez-Angulo A, Sneige N. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcome. J. Clins Oncol. 2005;23(1):41-8.

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.

Vinnicombe SJ, Mac Vicar AD, Guy RL. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathological correlation. Radiol.1996;198:333-40.

Fischer U, Kopka L, Grabbe E, Breast carcinoma: effect of preoperative contrast- enhancement MR imaging on the therapeutic approach. Radiol. 1999;213:881-8.

Greenstein OS. MR imaging of the breast. Radiol Clin North Am. 2000;38(4):899-913.

Quon A, Gambhir SS. FDG-PET and beyond: molecular cancer imaging. J Xlin Oncol. 2005;23:1664-73.

Waljee JF, Newman LA. Neoadjuvant systemic therapy and the surgical management of breast cancer. Surg Clin N Am. 2007;87:399-415.

Fisher ER, Wang J, Bryant J. Pathobiology of preoperative chemotherapy; finding from national surgical adjuvant breast and bowel protocol B-18. Cancer. 2002;95(4):681-95.

Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005;446:489-96.

Herrada J, Iyer RB, Atkinson EN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of primary tumour and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997;3:1565-9.

Schott ZF, Roubidoux MA, Helvie MA. Clinical and radiological assessments to predict breast cancer pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 92:231-8.